ENDEAR: Survival results

SPINRAZA® significantly improves event-free survival and overall survival in infantile-onset (Type I) SMA1

Event-free survival (primary endpoint)*1

Overall survival1

*Permanent ventilation defined as ≥16 hours ventilation/day continuously for >21 days in the absence of an acute reversible event or tracheostomy.1

Sofia
age 4½ years*
Infantile-onset (Type I) SMA
treated with SPINRAZA®
~4 years as of 10/18

*Age at time of photo shoot.

References:
1. SPINRAZA® Summary of Product Characteristics.